Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg
Phase 3Completed 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Vasomotor Rhinitis
Conditions
Vasomotor Rhinitis, Seasonal Allergic Rhinitis
Trial Timeline
Aug 1, 2009 โ Nov 1, 2009
NCT ID
NCT00976209About Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg
Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg is a phase 3 stage product being developed by Bayer for Vasomotor Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00976209. Target conditions include Vasomotor Rhinitis, Seasonal Allergic Rhinitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00976209 | Phase 3 | Completed |
Competing Products
20 competing products in Vasomotor Rhinitis